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Purpose: Meta-analysis of randomized controlled trials (RCTs) – of a hip
powder of Rosa canina (rosehip) preparation for symptomatic treatment
of osteoarthritis (OA), in order to estimate the empirical efﬁcacy as a
pain-reducing compound.
Methods: RCTs from systematic searches were included if they explicitly
stated that OA patients were randomized to either rosehip or placebo.
The primary outcome was reduction in pain calculated as effect size
(ES), deﬁned as the standardized mean difference (SMD). As secondary
analysis the number of responders to therapy was analyzed as Odds
Ratios (OR), and expressed as the Number Needed to Treat (NNT).
Restricted Maximum Likelihood (REML) methods were applied for the
meta-analyses using mixed effects models.
Results: The three studies (287 patients and a median trial-duration
of 3 months) – all supported by the manufacturer (Hyben-Vital Interna-
tional) – showed a reduction in pain scores by rosehip powder (145 pa-
tients) compared to placebo (142 patients): ES of 0.37 [95% conﬁdence
interval (CI): 0.13−0.60], P = 0.002. Test for homogeneity seemed to
support that the efﬁcacy was consistent across trials (I-square = 0%).
Thus it seems reasonable to assume that the three studies were mea-
suring the same overall effect. It seemed twice as likely that a patient
allocated to rosehip powder would respond to therapy, compared to
placebo (OR=2.19; P=0.0009); corresponding to a NNT of six (95% CI:
4−13) patients (ﬁgure).
Conclusions: Although based on a sparse amount of data, the results of
the present meta-analysis indicate that rosehip powder does reduce pain;
accordingly it may be of interest as a nutraceutical, although its efﬁcacy
and safety need evaluation and independent replication in a future large-
scale/long-term trial.
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Purpose: Obesity and OA coexist in an increasing part of the population,
and the two diseases intertwine in several ways. Body-mass index (BMI)
is the single most important risk factor for knee OA and awareness of
the beneﬁt of weight reduction should be emphasized at all stages of the
disease.
To assess the association between the Kellgren-Lawrence (K-L) score
and BMI in obese patients with knee OA among the included patients and
explore whether the K-L score could predict the amount of weight loss
using low (LED) and very low-energy diets (VLED) in patients following
the Cambridge diet for 8 weeks in the CAROT-study (NCT00655941).
Methods: Prior to inclusion in the CAROT-study at the Parker Insti-
tute, Frederiksberg Hospital, and thus commencing the Cambridge-diet
program, we obtained standing radiographs from 47 obese (BMI> 30)
patients suffering from OA in one or both knees, to fulﬁl both the clinical
and radiological ACR criteria for knee OA. The subjects were also
>50 years, spoke Danish and were motivated for weight loss. Exclusion
criteria were: bilateral alloplasty of the knees; ongoing or planned surgery;
ongoing or planned alternative weight loss programme; and intellectual
disability. The mean age of the population was 62.8 years (SD: 6.9;
range: 50−75 y), with only three (6.4%) of the patients being males. The
radiographic severity of OA was assessed using the K-L scale for the
medial, lateral and patellar compartments. A total K-L-score (sum of all 3
compartments) was calculated (range:0−12). All patients were weighed
before and after the 8 weeks diet period with the same equipment.
The statistical analysis was based on a non-responder intention-to-treat
(ITT) population (baseline observation carried forward). In the diet period
the patients only consumed products from the ‘Cambridge Health &
Weight Plan’, providing them a daily calorie intake between 415 kCal and
810 kCal.
Results: The median total K-L score was 5 (1−10), medial compartment
2 (0−4), lateral compartment 1 (0−3), and the patellar compartment 2
(0−4). Before the diet period the patients had a mean BMI of 38.0 kg/m2
(SD: 3.6; 31.0−48.4) corresponding to an average body weight of 102.4 kg
(SD:13.2; 84.4–143.8 kg). There was no correlation between K-L score
and BMI at baseline (r = 0.21; P=0.17) with less than ﬁve percent of
the variation in K-L score being explained by the BMI (R-squared <5%).
After the diet period of 8 weeks only one patient (2.1%) withdrew from
the project, however, the ITT patients (n = 47) experienced a highly
signiﬁcant weight reduction (P< 0.0001) of 11.4 kg (95%CI 10.2−12.5 kg),
corresponding to an average loss of 11.0% of the initial body weight. The
percentage of body weight lost was not associated with the K-L score
neither of the whole joint nor its separate compartments.
Conclusions: In this group of obese Danish patients with knee OA there
was no indication of a correlation between radiographic severity and
BMI. The K-L score was not associated with the amount of weight-loss.
Whereas knee OA may often be perceived as a barrier to successful
weight loss these patients achieved meaningful weight-loss on the ‘Cam-
bridge Health & Weight Plan’. This suggests that any knee OA patient
with concomitant obesity may be enrolled in an effective weight reducing
program. The results show that radiographic knee status is not important
for a weight loss: In other words, bad knees are no excuse for not loosing
weight.
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Purpose: To examine whether the effects of 12 weeks of quadriceps
strengthening on the knee adduction moment (KAM), pain and function
in people with medial knee OA differ in those with and without varus
malalignment.
Methods: A single-blind randomized controlled trial involving 107 com-
munity volunteers with medial knee OA was conducted. Participants
were stratiﬁed according to knee malalignment (more varus or more
neutral) and then randomized into either a 12-week supervised home
based quadriceps strengthening (QS) group or a control group with no
intervention. The primary outcome was the KAM measured using three-
dimensional gait analysis. Secondary outcomes included the Western
Ontario and McMaster Universities Osteoarthritis Index (WOMAC) mea-
suring pain and physical function, step test, stair climb test and maximum
quadriceps isometric strength. Analyses of covariance were carried out
based on intention-to-treat principles.
Results: Quadriceps strengthening did not signiﬁcantly alter the KAM
in either the more malaligned or the more neutral group (unadjusted
